retatrutide parkinson's disease trial nct Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in trials Retatrutide produces up to 30.3%

N Engl J Med 2024;390:1394-407

Ideal Candidates You're likely a good candidate if you have BMI of 30+ (obesity) or 27+ with weight-related health conditions, have tried diet and exercise without sustained success, are ready to commit to healthier eating, want medically supervised, FDA-approved treatment, and can invest 6-12 months for optimal results

Hims has engaged in promotional campaigns that highlight its compounded semaglutide products, duping consumers and healthcare professionals as to the clinical benefits and safety of these unapproved drugs. Novo Nordisk Novo is seeking a permanent injunction and damages

Thyroid Tumors Studies raise concerns about thyroid cancer, which regulators are continuing to review

Public Health 180 , 2228 (2020)

Third, our approach: we'd rather under-treat and have you come back happy than over-treat and have you regret it